Wednesday, November 18, 2026

Elaine covers emerging obesity therapies, novel drug payment models, FDA impact on companies, and the growing psychedelics market. She co‑writes The Readout newsletter and co‑hosts STAT’s weekly biotech podcast, The Readout Loud. Reach her on Signal at elaineywchen.70.

Stay current with the science and policy shaping biotech. Sign up for our biotech newsletter.

Good morning. We have a busy news day, highlighting significant oncology updates.

Key biotech news this morning

Sellas immunotherapy reduces AML mortality risk

Sellas Life Sciences’ experimental therapy lowered the risk of death by 41% versus standard care for patients with advanced acute myeloid leukemia, the company announced.






Source link

Exit mobile version